Jeff Yass’s CG Oncology CGON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$46.2M Buy
650,200
+273,500
+73% +$17.9M ﹤0.01% 1591
2026
Q1
$25.5M Buy
376,700
+133,900
+55% +$7.59M ﹤0.01% 1921
2025
Q4
$10.1M Buy
242,800
+192,300
+381% +$7.96M ﹤0.01% 3027
2025
Q3
$2.03M Sell
50,500
-1,000
-2% -$29.1K ﹤0.01% 5763
2025
Q2
$1.34M Buy
51,500
+21,200
+70% +$511K ﹤0.01% 6709
2025
Q1
$742K Sell
30,300
-133,100
-81% -$3.74M ﹤0.01% 8008
2024
Q4
$4.69M Buy
163,400
+110,300
+208% +$3.77M ﹤0.01% 3695
2024
Q3
$2M Buy
+53,100
New +$1.86M ﹤0.01% 5260

Other funds holding CGON

Jeff Yass's CGON Position: Q2 2026 in Review

Jeff Yass reduced its CG Oncology (CGON) stake by 39% in Q2 2026, selling an estimated $663K and leaving 15,653 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7927.

Jeff Yass first reported a position in CGON in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.44M in Q2 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Jeff Yass held 15,653 shares of CG Oncology worth $1.11M as of Q2 2026.
  • Jeff Yass sold 10,150 CG Oncology shares in Q2 2026, an estimated $663K.
  • CG Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7927 holding.
  • Jeff Yass first reported a position in CG Oncology in Q1 2024 and has held it in 7 quarters since.
  • Jeff Yass's CG Oncology position peaked at $2.44M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.